ConductScience.org, home

Comparison · NCT04760782-deaths

Treatment Group vs Historical Control Group: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment Group vs Historical Control Group: deaths from any cause. Trial comparisons, record NCT04760782-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04760782-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.20.03620.624wilson
Risk in group 2000.658wilson
Risk difference, group 1 minus group 20.2-0.4780.624newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Treatment Group than on Historical Control Group5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treatment Group
Daily self-administered injection of 80 mcg abaloparatide (8 weeks) + hard collar immobilization (12 weeks)~Abaloparatide: Abaloparatide 80 mcg by subcutaneous, self-administered injection once per day (8 weeks)~Hard collar immobilization: Hard collar immobilization of the cervical spine for 12 weeks
15EG000
Group 2Historical Control GroupPatients who received only 12 weeks of hard collar immobilization~Hard collar immobilization: Hard collar immobilization of the cervical spine for 12 weeks02EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Treatment group: Adverse events collected prospectively for participants enrolled to the treatment group from study consent through the 12-week study visit or until participant withdrawal/discontinuation, whichever was first. Active control participants: Adverse events collected prospectively from study consent through completion of research procedures (duration of 1 study visit only). Historical Control participants: Adverse events not reviewed retrospectively.

Source ClinicalTrials.gov

Trial

Title
PTH Analog Type II Odontoid Fracture
NCT number
NCT04760782
Phases
PHASE2
Conditions
Odontoid Fracture
Interventions
Abaloparatide, Hard collar immobilization
Lead sponsor
David Lunardini
Results first posted
2024-09-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04760782-deaths